• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特定自身抗体与正常眼压性青光眼

Selected autoantibodies and normal-tension glaucoma.

作者信息

Skonieczna Katarzyna, Grabska-Liberek Iwona, Terelak-Borys Barbara, Jamrozy-Witkowska Agnieszka

机构信息

Department of Ophthalmology, Medical Centre of Postgraduate Education, Warsaw, Poland.

出版信息

Med Sci Monit. 2014 Jul 13;20:1201-9. doi: 10.12659/MSM.890548.

DOI:10.12659/MSM.890548
PMID:25016491
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4106929/
Abstract

BACKGROUND

Although intraocular pressure is an important risk factor in glaucoma, there is growing body evidence indicating an immunological component in the pathogenesis of normal-tension glaucoma (NTG). The aim of this study was to determine if NTG coexists with elevated levels of autoantibodies detected in rheumatic diseases.

MATERIAL AND METHODS

We enrolled 105 patients into the study: 35 with NTG, 34 with primary open-angle glaucoma (POAG), and 36 controls. All patients underwent ophthalmic examination and blood tests. Blood was examined for the level of: antibodies against antinuclear antibodies (ANA), antibodies to extractable nuclear antigens (ENA), immunoglobulins (IgG, IgA, IgM), rheumatoid factor, anti-citrullinated protein antibodies (ACPA), and antiphospholipid antibodies (anticardiolipin antibodies, beta2-glycoprotein I antibodies, antiprothrombin antibodies).

RESULTS

The level of ANA was increased among 6 patients in the NTG group (17.1%), 8 in the POAG group (23.5%), and 6 in the control group (16.5%). The difference was not statistically significant (p=0.97). None of the patients in the NTG, POAG, or control group had positive antibodies to ENA. The level of immunoglobulins IgG, IgM, and IgA in the 3 groups was similar and within normal values. The median level of rheumatoid factor and ACPA was the highest in the NTG group, but it was within normal laboratory values. There was a statistically significant difference between antiprothrombin antibodies IgG between the NTG and POAG group (p=0.01), but not between the NTG and control group (p=0.24).

CONCLUSIONS

The results of our study do not confirm the hypothesis that NTG coexists with elevated blood levels of antibodies, which are a characteristic feature of rheumatic diseases.

摘要

背景

尽管眼压是青光眼的一个重要危险因素,但越来越多的证据表明,正常眼压性青光眼(NTG)的发病机制中存在免疫成分。本研究的目的是确定NTG是否与在风湿性疾病中检测到的自身抗体水平升高同时存在。

材料与方法

我们招募了105名患者参与研究:35名NTG患者、34名原发性开角型青光眼(POAG)患者和36名对照者。所有患者均接受眼科检查和血液检测。检测血液中的以下指标水平:抗核抗体(ANA)、可提取核抗原抗体(ENA)、免疫球蛋白(IgG、IgA、IgM)、类风湿因子、抗瓜氨酸化蛋白抗体(ACPA)和抗磷脂抗体(抗心磷脂抗体、β2糖蛋白I抗体、抗凝血酶原抗体)。

结果

NTG组有6名患者(17.1%)ANA水平升高,POAG组有8名患者(23.5%)ANA水平升高,对照组有6名患者(16.5%)ANA水平升高。差异无统计学意义(p = 0.97)。NTG组、POAG组或对照组中均无患者ENA抗体呈阳性。三组中免疫球蛋白IgG、IgM和IgA的水平相似且在正常范围内。NTG组类风湿因子和ACPA的中位数水平最高,但在实验室正常范围内。NTG组和POAG组之间抗凝血酶原抗体IgG存在统计学显著差异(p = 0.01),但NTG组和对照组之间无差异(p = 0.24)。

结论

我们的研究结果未证实NTG与血液中抗体水平升高同时存在的假设,而抗体水平升高是风湿性疾病的一个特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/ca2f05895e60/medscimonit-20-1201-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/345943452219/medscimonit-20-1201-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/5a51eb930574/medscimonit-20-1201-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/b04bde444ef2/medscimonit-20-1201-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/0219c3d4d74b/medscimonit-20-1201-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/229ece472d19/medscimonit-20-1201-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/2294173a0d7c/medscimonit-20-1201-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/ca2f05895e60/medscimonit-20-1201-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/345943452219/medscimonit-20-1201-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/5a51eb930574/medscimonit-20-1201-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/b04bde444ef2/medscimonit-20-1201-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/0219c3d4d74b/medscimonit-20-1201-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/229ece472d19/medscimonit-20-1201-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/2294173a0d7c/medscimonit-20-1201-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf21/4106929/ca2f05895e60/medscimonit-20-1201-g007.jpg

相似文献

1
Selected autoantibodies and normal-tension glaucoma.特定自身抗体与正常眼压性青光眼
Med Sci Monit. 2014 Jul 13;20:1201-9. doi: 10.12659/MSM.890548.
2
Prevalence of serum autoantibodies and paraproteins in patients with glaucoma.青光眼患者血清自身抗体和副蛋白的患病率。
Eye (Lond). 2008 Mar;22(3):349-53. doi: 10.1038/sj.eye.6702613. Epub 2006 Oct 27.
3
[Preliminary study on the measurement of optic nerve subarachnoid space in patients with normal tension glaucoma].[正常眼压性青光眼患者视神经蛛网膜下腔测量的初步研究]
Zhonghua Yan Ke Za Zhi. 2018 Nov 11;54(11):827-832. doi: 10.3760/cma.j.issn.0412-4081.2018.11.006.
4
Comparison of macular ganglion cell complex thickness by Fourier-domain OCT in normal tension glaucoma and primary open-angle glaucoma.正常眼压性青光眼和原发性开角型青光眼的频域光相干断层扫描测量的黄斑神经节细胞复合体厚度比较。
J Glaucoma. 2013 Feb;22(2):133-9. doi: 10.1097/IJG.0b013e3182254cde.
5
[The function-structure impairment pattern of optic nerves in primary open-angle glaucoma and normal-tension glaucoma].[原发性开角型青光眼和正常眼压性青光眼视神经的功能-结构损害模式]
Zhonghua Yan Ke Za Zhi. 2018 Nov 11;54(11):811-819. doi: 10.3760/cma.j.issn.0412-4081.2018.11.004.
6
Antiphosphatidylserine antibodies are elevated in normal tension glaucoma.在正常眼压性青光眼中,抗磷脂酰丝氨酸抗体水平升高。
Clin Exp Immunol. 2001 Aug;125(2):211-5. doi: 10.1046/j.1365-2249.2001.01578.x.
7
Levels of antibodies against human heat shock protein (HSP) 60 in patients with glaucoma in Poland.波兰青光眼患者体内抗人热休克蛋白(HSP)60抗体的水平。
Med Sci Monit. 2015 Mar 19;21:828-32. doi: 10.12659/MSM.893349.
8
Interocular asymmetry of the visual field defects in newly diagnosed normal-tension glaucoma, primary open-angle glaucoma, and chronic angle-closure glaucoma.初诊正常眼压性青光眼、原发性开角型青光眼和慢性闭角型青光眼的视野缺损的双眼间不对称性。
J Glaucoma. 2014 Sep;23(7):455-60. doi: 10.1097/IJG.0b013e3182946553.
9
Comparison of retinal nerve fiber layer and macular thickness for discriminating primary open-angle glaucoma and normal-tension glaucoma using optical coherence tomography.使用光学相干断层扫描比较视网膜神经纤维层和黄斑厚度以鉴别原发性开角型青光眼和正常眼压性青光眼。
Clin Exp Optom. 2016 Jul;99(4):373-81. doi: 10.1111/cxo.12366. Epub 2016 Mar 21.
10
Analysis of Plasma Hydrogen Sulfide, Homocysteine, and L-Cysteine in Open-Angle Glaucoma Patients.分析原发性开角型青光眼患者血浆中硫化氢、同型半胱氨酸和 L-半胱氨酸的水平。
J Ocul Pharmacol Ther. 2020 Oct;36(8):649-657. doi: 10.1089/jop.2020.0023. Epub 2020 Jun 3.

引用本文的文献

1
Evaluating the association between autoimmune disease and normal tension glaucoma: a retrospective case-control study.评估自身免疫性疾病与正常眼压性青光眼之间的关联:一项回顾性病例对照研究。
BMC Ophthalmol. 2025 Feb 11;25(1):73. doi: 10.1186/s12886-025-03893-4.
2
Subclinical hypothyroidism and anti-thyroid peroxidase antibodies in primary open-angle glaucoma: A case-control study.原发性开角型青光眼患者的亚临床甲状腺功能减退症及抗甲状腺过氧化物酶抗体:一项病例对照研究。
Indian J Ophthalmol. 2024 Feb 1;72(2):228-231. doi: 10.4103/IJO.IJO_603_23. Epub 2023 Dec 15.
3
Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients.

本文引用的文献

1
Glaucoma.青光眼。
Lancet. 2011 Apr 16;377(9774):1367-77. doi: 10.1016/S0140-6736(10)61423-7. Epub 2011 Mar 30.
2
Primary open-angle glaucoma.原发性开角型青光眼
N Engl J Med. 2009 Mar 12;360(11):1113-24. doi: 10.1056/NEJMra0804630.
3
Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.加拿大青光眼研究:2. 开角型青光眼进展的危险因素
近期获批的用于降低和控制眼压以减少高眼压症和青光眼患者视力丧失的药物。
Pharmaceuticals (Basel). 2023 May 26;16(6):791. doi: 10.3390/ph16060791.
4
Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies.治疗高眼压症和青光眼的治疗药物与设备,以及神经保护和细胞保护疗法的必要性。
Front Pharmacol. 2021 Sep 17;12:729249. doi: 10.3389/fphar.2021.729249. eCollection 2021.
5
Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy.合成多克隆来源的互补决定区肽作为青光眼治疗的创新策略。
J Clin Med. 2019 Aug 15;8(8):1222. doi: 10.3390/jcm8081222.
6
Glaucoma -state of the art and perspectives on treatment.青光眼——治疗的现状与展望
Restor Neurol Neurosci. 2016;34(1):107-23. doi: 10.3233/RNN-150599.
7
Levels of antibodies against human heat shock protein (HSP) 60 in patients with glaucoma in Poland.波兰青光眼患者体内抗人热休克蛋白(HSP)60抗体的水平。
Med Sci Monit. 2015 Mar 19;21:828-32. doi: 10.12659/MSM.893349.
Arch Ophthalmol. 2008 Aug;126(8):1030-6. doi: 10.1001/archopht.126.8.1030.
4
Analytical aspects of thyroid antibodies estimation.甲状腺抗体检测的分析方面
Autoimmunity. 2008 Feb;41(1):46-54. doi: 10.1080/08916930701619466.
5
Factors associated with elevated serum concentrations of anti-TPO antibodies in subjects with and without diffuse goitre. Results from the Ukrainian-American Cohort Study of thyroid cancer and other thyroid diseases following the Chornobyl accident.与有弥漫性甲状腺肿和无弥漫性甲状腺肿受试者血清抗甲状腺过氧化物酶抗体浓度升高相关的因素。切尔诺贝利事故后乌克兰-美国甲状腺癌和其他甲状腺疾病队列研究的结果。
Clin Endocrinol (Oxf). 2007 Dec;67(6):879-90. doi: 10.1111/j.1365-2265.2007.02979.x.
6
Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study.抗凝血酶原抗体可预测系统性红斑狼疮患者的血栓形成:一项15年的纵向研究。
J Thromb Haemost. 2007 Jun;5(6):1158-64. doi: 10.1111/j.1538-7836.2007.02532.x.
7
Glaucoma.青光眼
Chem Immunol Allergy. 2007;92:221-227. doi: 10.1159/000099273.
8
Prevalence of serum autoantibodies and paraproteins in patients with glaucoma.青光眼患者血清自身抗体和副蛋白的患病率。
Eye (Lond). 2008 Mar;22(3):349-53. doi: 10.1038/sj.eye.6702613. Epub 2006 Oct 27.
9
Clinical and laboratory aspects of thyroid autoantibodies.甲状腺自身抗体的临床与实验室特征
Ann Clin Biochem. 2006 May;43(Pt 3):173-83. doi: 10.1258/000456306776865043.
10
Primary open-angle glaucoma.原发性开角型青光眼
Lancet. 2004 May 22;363(9422):1711-20. doi: 10.1016/S0140-6736(04)16257-0.